Attached files
| file | filename |
|---|---|
| EX-99.1 - PRESS RELEASE - Medite Cancer Diagnostics, Inc. | ex99-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report
(Date of earliest event reported): February 16,
2017
MEDITE CANCER DIAGNOSTICS, INC.
(Exact
Name of Registrant as Specified in Charter)
Delaware
(State
or Other Jurisdiction of Incorporation)
|
333-143570
|
36-4296006
|
|
(Commission
File Number)
|
(IRS
Employer Identification No.)
|
|
4203 SW 34th St.
|
|
|
Orlando,
FL
|
32811
|
|
(Address
of Principal Executive Offices)
|
(Zip
Code)
|
(407)
996-9630
(Registrant’s
telephone number, including area code)
(Former
Name or Former Address, if Changed Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2.
below):
|
|
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
|
|
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
|
Item 5.02 Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers
Director Vacancy Appointment
On
February 16, 2017, the Board of Directors, by unanimous written
consent, elected Eric Goehausen to the Board of Directors of the
Company to fill the vacancy resulting from the termination of
Robert F. McCullough, Jr., to serve as a Director until such time
as his resignation or removal.
Eric
M. Goehausen, Age 40, Director
Eric M. Goehausen has been the managing member of New Harbor
Merchant Partners, a private family investment office that invests
in growth-oriented businesses and special situations since 2003.
Mr. Goehausen also currently serves as the Director of Revenue
Growth of the Clinical Solutions Team of Anthem, Inc., a Fortune 30
company.
Mr. Goehausen has more than 17 years of corporate advisory, CFO and
executive-level financial management responsibilities, having led
all facets of financial operations including financial, planning
and analysis; accounting; treasury; profit improvement; M&A
activity; bank and Board reporting and compliance; restructuring
and transformational events for private-equity owned and public
companies ranging from $100M to $4B in revenue.
Mr. Goehausen started his career in investment banking with
JPMorgan Chase in 1998, where he focused on mergers, acquisitions,
leveraged buyouts, and corporate financings. In 2003, Eric
formed New Harbor Merchant Partners, a private investment firm
focused on providing strategic capital and advisory services to
middle market companies and business leaders. From 2006 through
2011, Mr. Goehausen was with the global professional services firm
Alvarez & Marsal where he focused on restructuring, turnaround
advisory and interim management of private equity controlled and
public companies with revenue ranging from $100 million to $4
billion. Mr. Goehausen was then Vice President of Corporate
Development for a publicly-traded dental products manufacturing
company prior to its sale, and subsequently Chief Financial Officer
of a private equity controlled education management
company.
Mr. Goehausen earned his Master of Business Administration, With
Honors, from The University of Chicago Booth School of Business
with concentrations in Accounting, Finance and Entrepreneurship,
and earned his Bachelor of Science in Business with a major in
Finance, Cum Laude, from Miami University in Oxford, OH. He
has completed advanced studies in Corporate Finance and
International Securities Markets at the London School of Economics,
as well as Financial Markets, Institutions and Money & Banking
at Northwestern University, and holds his CIRA
certification.
Mr.
Goehausen has not, and does not now serve as an officer or director
of any other company required to file reports with the
SEC.
Mr.
Goehausen’s compensation to serve as a Director shall be the
same as paid to other members of the Board of Directors of the
Company and in accordance with the Company’s compensation
plan as adopted by the Board of Directors and to be approved by the
shareholders of the Company.
Item 9.01 Financial Statements and Exhibits.
Exhibit 99.1.
Press Release
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
MEDITE
CANCER DIAGNOSTICS, INC.
|
|
|
|
|
|
|
|
|
|
|
Date:
February 23, 2017
|
By:
|
/s/ David E. Patterson
|
|
|
|
David
E. Patterson
|
|
|
|
Chief
Executive Officer
|
|
|
||